Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.

@article{DueasGonzlez2011PhaseIO,
  title={Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.},
  author={Alfonso Due{\~n}as-Gonz{\'a}lez and Juan Jos{\'e} Zarb{\'a} and Firuza Patel and Juan Carlos Alcedo and Semir Be{\vs}lija and Lu{\'i}s Casanova and Pittayapoom Pattaranutaporn and Shahid Hameed and Julie Michelle Blair and Helen Barraclough and Mauro Orlando},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 13},
  pages={1678-85}
}
PURPOSE To determine whether addition of gemcitabine to concurrent cisplatin chemoradiotherapy and as adjuvant chemotherapy with cisplatin improves progression-free survival (PFS) at 3 years compared with current standard of care in locally advanced cervical cancer. PATIENTS AND METHODS Eligible chemotherapy- and radiotherapy-naive patients with stage IIB to IVA disease and Karnofsky performance score ≥ 70 were randomly assigned to arm A (cisplatin 40 mg/m(2) and gemcitabine 125 mg/m(2… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
97 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 97 extracted citations

Similar Papers

Loading similar papers…